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Background.  This study assessed levels, trends, and associations of observed syphilis prevalence in the general adult population 
using global pooled analyses.
Methods. A standardized database of syphilis prevalence was compiled by pooling systematically gathered data. Random-
effects meta-analyses and meta-regressions were conducted using data from the period 1990–2016 to estimate pooled meas-
ures and assess predictors and trends. Countries were classified by World Health Organization region. Sensitivity analyses were 
conducted.
Results. The database included 1103 prevalence measures from 136 million syphilis tests across 154 countries (85% from women 
in antenatal care). Global pooled mean prevalence (weighted by region population size) was 1.11% (95% confidence interval [CI], 
.99–1.22). Prevalence predictors were region, diagnostic assay, sample size, and calendar year interacting with region. Compared to 
the African Region, the adjusted odds ratio (AOR) was 0.42 (95% CI, .33–.54) for the Region of the Americas, 0.13 (95% CI, .09–.19) 
for the Eastern Mediterranean Region, 0.05 (95% CI, .03–.07) for the European Region, 0.21 (95% CI, .16–.28) for the South-East 
Asia Region, and 0.41 (95% CI, .32–.53) for the Western Pacific Region. Treponema pallidum hemagglutination assay (TPHA) only or 
rapid plasma reagin (RPR) only, compared with dual RPR/TPHA diagnosis, produced higher prevalence (AOR >1.26), as did smaller 
sample-size studies (<500 persons) (AOR >2.16). Prevalence declined in all regions; the annual AORs ranged from 0.84 (95% CI, 
.79–.90) in the Eastern Mediterranean to 0.97 (95% CI, .97–1.01) in the Western Pacific. The pooled mean male-to-female prevalence 
ratio was 1.00 (95% CI, .89–1.13). Sensitivity analyses confirmed robustness of results.
Conclusions. Syphilis prevalence has declined globally over the past 3 decades. Large differences in prevalence persist among 
regions, with the African Region consistently the most affected.
Keywords. sexually transmitted infection; surveillance; diagnostic assay; meta-analysis; meta-regression.
 
In 2016, the World Health Assembly and its member states 
adopted the World Health Organization’s (WHO) Global Health 
Sector Strategy on Sexually Transmitted Infections (STIs), 
2016–2021 [1]. The strategy aims to reduce syphilis and gonor-
rhea incidence over 2018–2030 by 90%, and to reduce the inci-
dence of congenital syphilis to <50 cases per 100 000 live births 
by 2030 [1]. However, levels and trends in adult and congenital 
syphilis prevalence and incidence remain uncertain [2], with 
recent evidence suggesting increases [3], particularly among 
men who have sex with men (MSM), where several countries 
reported the largest increases in many years [4–6].
Our study had 5 aims to inform syphilis burden estimates: 
(1) to create a global database of adult syphilis prevalence in 
the general population post-1970; (2) to pool prevalence data 
globally and by region; (3) to assess the association between 
prevalence and region, surveyed general population type, 
sex, and diagnostic assay; (4) to estimate the overall tempo-
ral trend in prevalence by region; and (5) to inform model 
assumptions and parameters, most notably the Spectrum-
STI model being developed to estimate national-level STI 
burdens [7].
METHODS
We compiled a standardized global database of syphilis preva-
lence in the adult general population (Global Syphilis Prevalence 
Database), drawing data from the following:
1. Global AIDS Response Progress Reporting (GARPR) system, 
more recently called the Global AIDS Monitoring system [8] 
(last accessed in July 2016);
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2. Institute of Health Metrics and Evaluation (IHME) database 
compiled for the 2015 Global Burden of Disease study [9] 
(last accessed in November 2016);
3. WHO-STI database compiled for the 2005 [10] and 2008 [11] 
global and regional estimates.
Other data sources included a major systematic review for STIs 
in sub-Saharan Africa [12]; national surveillance reports com-
piled by the ministries of health of Zimbabwe [7], Morocco 
[7], and Mongolia (unpublished data), during pilot national 
STI estimations using the Spectrum-STI model; and a national 
human immunodeficiency virus (HIV)/syphilis household 
survey conducted in 2016 in Zimbabwe [13].
The extracted GARPR data included prevalence measures 
among women screened at antenatal care (ANC), and reported 
by national health ministries based on either routine ANC pro-
grammatic screening or nationally representative surveys.
The extracted IHME data were based on a PubMed system-
atic search using broad search terms for post-1990 data, and ex-
traction of testing data from reports in the Global Health Data 
Exchange [14] database maintained by IHME. Inclusion of data 
was restricted to those in the general population with exclusion 
of blood donors (because of exclusion of self-reported risks), 
and high-risk and other nonrepresentative populations.
The extracted WHO-STI data included nationally or subna-
tionally representative general population surveys of sample 
size >100 and published after 2000. Probable active syphilis 
infection was defined as concurrent positive serology on both 
nontreponemal and treponemal assays per the WHO [15] and 
IHME definitions. Nontreponemal laboratory diagnosis was 
classified as “RPR” testing as it was done using rapid plasma re-
agin (RPR) or the similar Venereal Disease Research Laboratory 
(VDRL) assay [16]. The treponemal laboratory diagnosis was 
classified as “TPHA” as it was usually done using the Treponema 
pallidum hemagglutination assay (TPHA) or similar assay.
At least 1 reviewer evaluated each data point based on our 
inclusion criteria: (1) specimens collected between 1970 and 
2016; (2) study population considered representative of the gen-
eral population; (3) no apparent participant selection bias (eg, 
patients seeking care for genital symptoms were excluded); and 
(4) studies used nontreponemal and/or treponemal assays on 
serum samples. Suspected duplicates were removed.
Information extracted included prevalence, sample size, 
diagnostic assay, sex, and population type. The diagnostic 
assay was categorized as RPR/TPHA; TPHA only, in ANC or 
family planning (FP) population; TPHA only, in non-ANC/
non-FP population; RPR only; rapid treponemal-based assay; 
and assay unknown. “TPHA only” was split into 2 categories 
because TPHA positivity is a marker of cumulative exposure 
that increases with age and thus should be lower in the younger 
ANC/FP women compared with other women [7]. Sample size 
was imputed for few ANC data points through linear interpol-
ation between years with reported sample sizes.
Countries were grouped by WHO region [17]: African 
Region (AFRO) including most of Africa; Region of the 
Americas (AMRO) including North/Central/South America; 
South-East Asia Region (SEARO) including South Asia (eg, 
India) and part of South-East Asia (eg, Indonesia); European 
Region (EURO) including Europe and Central Asia; Eastern 
Mediterranean Region (EMRO) including Middle East and 
North Africa and part of the Horn of Africa; and Western 
Pacific Region (WPRO) including East Asia (eg, China), part of 
South-East Asia, Australia, and Oceania.
Meta-analyses
Global and regional mean syphilis prevalence (and corresponding 
confidence intervals [CIs]) were estimated by pooling prevalence 
measures. With the small number of measures pre-1990, these 
data were excluded from main meta-analysis as they may not be 
representative for 1970–1990. A meta-analysis including data over 
46 years (1970–2016) was conducted as a sensitivity analysis.
The pooled means were estimated using DerSimonian and 
Laird random-effects models [18]. This meta-analytic approach 
accounts for sampling variation and heterogeneity in effect size 
(here syphilis prevalence) [19]. The variances of prevalence 
measures were stabilized using a Freeman-Tukey–type arcsine 
square-root transformation [20, 21], and then weighted using 
the inverse-variance method [19, 21]. The weights accommo-
date for the variance arising from sampling variation as well as 
distribution of true effect size [19, 21].
Cochran’s Q-test was conducted to assess the existence of het-
erogeneity in effect size [19, 22]. The I2 measure was estimated 
to assess the proportion of between-study variation in effect size 
that is due to actual differences in effect size across studies rather 
than chance. The prediction interval was estimated to assess the 
distribution of true effects around the estimated mean [19, 23].
The pooled mean male-to-female ratio of syphilis preva-
lence was assessed using studies that reported prevalence in 
men and women within the same population at the same time. 
The ratio was estimated using random-effects meta-analyses as 
described above.
Meta-analyses were conducted in R version 3.3.1 software 
[24] using the package meta [25] except for the male-to-female 
ratio, which was conducted using the package metafor [26].
Meta-regressions
Random-effects meta-regression models were used to identify 
predictors of syphilis prevalence (and male-to-female preva-
lence ratio) and sources of between-study heterogeneity. Pre-
1990 data were excluded from main meta-regression, but a 
meta-regression including all data (1970–2016) was conducted 
as a sensitivity analysis.
The following independent variables and interaction were 
specified a priori because of relevance to the study’s questions: 
region, population type, sample size (dichotomized as ≥500 or 
<500 persons), diagnostic assay, time (linear measure specified 
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by year, and then centered by mean year), and time region´  
interaction. The time region´  interaction was included to 
measure the annual rate of decline in the odds of syphilis pos-
itivity for each region separately, as opposed to a global rate 
of decline. Syphilis prevalence was generally low; the annual 
odds ratio for syphilis positivity can be interpreted (approxi-
mately) as the average annual proportional decline in syphilis 
prevalence, in the given region. Factors associated with prev-
alence with P ≤ .1 in univariate analysis were included in the 
final multivariable model. Factors associated with prevalence 
with P ≤ .05 in the final multivariable model were considered 
statistically significant. Inverse variance weighting was used in 
all meta-regressions.
For sensitivity analyses, to confirm identified trends given 
the variation in data availability with time, we repeated the 
same meta-regression analysis plan but excluded all pre-1995 
and pre-2000 data. Also to confirm identified trends, we con-
ducted sensitivity analyses by excluding small sample-size stud-
ies (<500) and studies using an assay besides RPR/TPHA.
All meta-regressions were conducted in R version 3.3.1 soft-
ware [24] using the package metafor [26].
RESULTS
Scope of Syphilis Prevalence Data
The database included 1103 prevalence measures from 154 
countries carried out between 1972 and 2016. Year 2010 was 
the median year. Of the 136 million syphilis tests, 1.4 million 
(1.0%) were syphilis positive (Table 1). The median prevalence 
was 1.4%. Most data were from ANC women (84.8%), including 
both routine-care screening (44.3%) and ANC-based sentinel 
surveys (40.5%). Just over 50% of surveys used RPR/TPHA dual 
positivity for defining syphilis. AFRO had the largest number 
of surveys, but WPRO had the largest number of people tested. 
Most data were collected post-2000 (82.5%). Number of people 
tested increased with time, peaking in 2014.
Meta-analyses of Syphilis Prevalence
Meta-analyses (for 1990–2016 data) estimated the pooled mean 
regional syphilis prevalence at 3.04% (95% CI, 2.84%–3.24%) in 
AFRO, 0.97% (95% CI, .82%–1.13%) in AMRO, 0.63% (95% CI, 
.46%–.82%) in EMRO, 0.12% (95% CI, .09%–.15%) in EURO, 
0.65% (95% CI, .56%–.75%) in SEARO, and 1.27% (95% CI, 
1.18%–1.36%) in WPRO (Table  2). The global (unweighted) 
mean prevalence was 1.61% (95% CI, 1.51%–1.71%). Weighted 
by region population size, the global mean prevalence was lower 
at 1.11% (95% CI, .99%–1.22%), reflecting lower prevalence in 
populous regions such as SEARO. The meta-analysis including 
all data (1970–2016) arrived at similar results (Supplementary 
Table 1).
There was significant evidence for heterogeneity in effect size 
(syphilis prevalence) within all regions; the P value was always 
<.0001. Most variability was attributed to differences in effect 
size rather than chance (I2 > 99.5%). However, the prediction 
intervals were relatively narrow, indicating only moderate vari-
ation in prevalence across studies.
Meta-regression for Syphilis Prevalence
Univariate meta-regression analyses of syphilis prevalence 
(1990–2016) data selected the variables region, sample size, 
population type, diagnostic assay, and time region´  interac-
tion for inclusion in the final multivariable model (Table 3). The 
final model’s adjusted R2 was 47.16%. AFRO had the highest 
prevalence. Relative to AFRO, the adjusted odds ratios (AORs) 
were 0.42 (95% CI, .33–.54) for AMRO, 0.13 (95% CI, .09–.19) 
for EMRO, 0.05 (95% CI, .03–.07) for EURO, 0.21 (95% CI, .16–
.28) for SEARO, and 0.41 (95% CI, .32–.53) for WPRO.
The meta-regression yielded adjustment factors for the 
diagnostic assays. Compared to studies using RPR/TPHA for 
diagnosis, studies diagnosing with TPHA only in the ANC/FP 
populations had >2-fold higher odds of test positivity (AOR, 
2.41 [95% CI, 1.36–4.22]). Studies diagnosing with TPHA only 
in non-ANC/non-FP populations had nearly 3-fold higher 
odds (AOR, 2.71 [95% CI, 1.39–5.27]). Studies utilizing RPR 
only also had higher odds (AOR, 1.26 [95% CI, 1.04–1.53]).
Small study sample size (<500) was associated with higher 
prevalence. The AOR was 2.16 (95% CI, 1.60–2.92).
The AORs for the time region´  interaction term were all <1, 
indicating declining syphilis prevalence in all regions, but this 
decline was not statistically significant for EURO and WPRO. 
AORs (per year) were 0.95 (95% CI, .93–.97) for AFRO, 0.92 (95% 
CI, .88–.97) for AMRO, 0.84 (95% CI, .79–.90) for EMRO, 0.94 
(95% CI, .87–1.03) for EURO, 0.90 (95% CI, .86–.94) for SEARO, 
and 0.97 (95% CI, .93–1.01) for WPRO. An AOR of 0.95 implies 
(approximately) a 5% annual decline in syphilis prevalence.
For sensitivity analyses, the above meta-regressions 
were redone on data collected for all times (1970–2016; 
Supplementary Table  2), post-1995 (Supplementary Table  3), 
and post-2000 (Supplementary Table 4). These yielded similar 
results for the trends and predictors, affirming the inherent 
consistency of the results and confirming the temporal declines 
in all regions. A meta-regression excluding studies with <500 
sample size, and another excluding studies using an assay be-
sides RPR/TPHA, both yielded also similar trends and predic-
tors (Supplementary Tables 5 and 6).
Meta-analysis and Meta-regression for the Male-to-Female 
Prevalence Ratio
Forty-three studies were identified (from 4 of the 6 regions) that 
included data from the same population at the same time for 
both men and women. The majority were from AFRO (67.4%), 
72% had ≥500 sample size, and 72% used RPR/TPHA dual pos-
itivity for diagnosis. Most studies were drawn from the pub-
lished literature.
The pooled mean male-to-female prevalence ratio was 
1.00 (95% CI, .89–1.13; Figure  1). The meta-regression 
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analyses did not identify any significant predictor for this ratio 
(Supplementary Table 7).
DISCUSSION
We presented analyses of 1103 syphilis prevalence measures 
representing 136 million tests from 154 countries over 4 dec-
ades. Prevalence has been declining for 3 decades, if not more, 
by several percentage points per year across the regions. While 
the global mean weighted (1990–2016) prevalence was 1.11%, 
regional prevalence varied widely, from 0.12% in EURO to 
3.04% in AFRO. The analyses yielded adjustment factors for the 
different diagnostic assays; diagnosis by other than RPR/TPHA 
dual-positivity overestimated prevalence. Small sample-size 
studies (<500) also overstated prevalence estimates. Prevalence 
did not differ between men and women in the subanalysis that 
investigated the male-to-female prevalence ratio.
The downward trends in prevalence in all regions were remark-
able. Though there were differences in the decline rates, the decline 
was consistent in all regions, suggesting a global phenomenon. 
Whether these declines reflect falls in incidence and/or shorter 
durations of active infection is unclear. The incidence may have 
Table 1. Summary of the Data Characteristics of the Global Syphilis Prevalence Database
Characteristic
No. (%) of Studies, Surveys, and Years of  
Routine ANC Screening
No. of Samples  
Tested
No. of Positive 
Samples
Median  
Prevalence, %
Prevalence 
Range, %
WHO region
 AFRO 488 (44.2) 30 390 450 963 400 2.7 0.0–22.1
 AMRO 206 (18.7) 22 455 430 194 161 0.8 0.0–15.1
 EMRO 63 (5.7) 20 24 670 3822 0.8 0.0–16.0
 EURO 86 (7.8) 14 134 541 19 154 0.7 0.0–2.2
 SEARO 110 (10.0) 15 258 147 43 169 0.6 0.0–5.8
 WPRO 150 (13.6) 51 280 258 137 149 1.2 0.0–16.7
 Global 1103 (100) 135 543 496 1 365 885 1.4 0.0–22.1
Sample size
 ≥500 998 (90.5) 135 514 522 1 359 562 1.25 0.0–20.3
 <500 105 (9.5) 28 974 1293 3.3 0.0–22.1
Data type
 ANC routine 489 (44.3) 130 148 057 1 264 180 0.6 0.0–16.7
 ANC survey 447 (40.5) 4 579 718 86 327 1.8 0.0–22.1
 Women survey 85 (7.7) 458 887 4770 1.9 0.0–21.8
 Men survey 74 (6.7) 230 351 4956 2.0 0.0–20.3
 Women and men survey 8 (0.7) 126 483 622 0.5 0.1–2.5
Diagnostic assay
 RPR/TPHA 564 (51.1) 82 698 827 400 024 1.1 0.0–18.7
 TPHA in ANC or FP 21 (1.9) 1 527 823 33 292 1.1 0.0–9.3
 TPHA in non-ANC or 
non-FP
20 (1.8) 29 755 2899 10.6 3.3–20.3
 RPR 285 (25.8) 25 247 224 519 171 1.9 0.0–22.1
 Rapid treponemal-based 
assay
36 (3.3) 6 649 547 72 051 1.4 0.1–8.75
 Assay unknown 177 (16.0) 19 390 320 333 418 0.9 0.0–14.1
Data collection period
 1972–1985 6 (0.5) 27 353 585 3.1 1.0–8.7
 1986–1990 15 (1.4) 34 536 478 7.5 0.4–16.0
 1991–1995 43 (3.9) 190 258 8142 8.7 0.1–21.8
 1996–2000 113 (10.2) 425 807 13 520 2.7 0.0–20.3
 2001–2005 178 (16.1) 1 209 566 26 584 1.7 0.0–17.2
 2006–2010 336 (30.6) 30 364 908 459 509 1.1 0.0–22.1
 2011 71 (6.4) 13 116 304 128 226 0.9 0.0–9.3
 2012 84 (7.6) 21 040 667 147 297 0.6 0.0–10.3
 2013 87 (7.9) 24 546 802 167134 0.4 0.0–13.7
 2014 86 (7.8) 27 467 301 229 868 0.9 0.0–13.5
 2015 81 (7.3) 13 791 174 175 548 1.1 0.1–16.7
 2016 2 (0.2) 80 000 640 0.8 0.6–1.0
 All years 1103 (100) 135 543 496 1 360 855 1.4 0.0–22.1
Abbreviations: AFRO, African Region; AMRO, Region of the Americas; ANC, antenatal care; EMRO, Eastern Mediterranean Region; EURO, European Region; FP, family planning; RPR, rapid 
plasma reagin; SEARO, South-East Asia Region; TPHA, Treponema pallidum hemagglutination assay; WHO, World Health Organization; WPRO, Western Pacific Region. 
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fallen due to the expansion of HIV/STI response including pri-
mary prevention interventions [1, 27], declines in sexual risk 
behavior in response to the threat of HIV infection [28], increased 
HIV-associated mortality that may have disproportionally affected 
people at higher STI risk [29], shorter duration of active infection 
in sex partners [30, 31], and possibly demographic, sociocultural, 
Table 2. Pooled Mean Estimates for Syphilis Prevalence Globally and by Region, 1990–2016
WHO Region
Studies, Surveys, and Years of 
Routine ANC Screening Samples Tested Prevalence, % Heterogeneity Measures
Total No. Total No. Mean (95% CI)
Qa  
(P Value)
I2, %b  
(95% CI)
Prediction Interval, %c 
(95% CI)
AFRO 480 30 386 735 3.04 (2.84–3.24) 497 920.82 (<.0001) 99.9 (99.9–99.9) (.2–8.9)
AMRO 205 22 453 896 0.97 (.82–1.13) 283 166.71 (<.0001) 99.9 (99.9–99.9) (.0–4.4)
EMRO 60 2 024 180 0.63 (.46–.82) 12 481.22 (<.0001) 99.5 (99.5–99.6) (.0–2.7)
EURO 86 14 134 541 0.12 (.09–.15) 23 597.66 (<.0001) 99.6 (99.6–99.7) (.0–0.6)
SEARO 110 15 258 147 0.65 (.56–.75) 48 374.37 (<.0001) 99.8 (99.8–99.8) (.·0–2.0)
WPRO 147 51 243 687 1.27 (1.18–1.36) 77 534.39 (<.0001) 99.8 (99.8–99.8) (.5–2.4)
Global 1088 135 501 186 1.61 (1.51–1.71) 2 326 538.45 (<.0001) 100.0 (100.0–100.0) (.0–6.5)
Abbreviations: AFRO, African Region; AMRO, Region of the Americas; ANC, antenatal care; CI,  confidence interval; EMRO, Eastern Mediterranean Region; EURO, European Region; 
SEARO, South-East Asia Region; WHO, World Health Organization; WPRO, Western Pacific Region.
aQ is the Cochran Q statistic assessing the existence of heterogeneity in effect size (syphilis prevalence).
bI2 is a measure assessing the magnitude of between-study variation that is due to differences in effect size across studies rather than chance.
cPrediction interval estimates the 95% interval in which the true effect size in a new study would lie. 
Table 3. Meta-regression Results for the Predictors of Adult Syphilis Prevalence Levels and Sources of Between-Study Heterogeneity, 1990–2016
Characteristic Variable
No. of Studies, Surveys, and Years of 
Routine ANC Screening
Univariate Analysis Multivariable Analysis
OR (95% CI) P Value AOR (95% CI) P Value
WHO region AFRO 480 1 1
AMRO 205 0.28 (.22–.35) <.0001 0.42 (.33–.54) <.0001
EMRO 60 0.13 (.09–.19) <.0001 0.13 (.09–.19) <.0001
EURO 86 0.03 (.02–.04) <.0001 0.05 (.03–.07) <.0001
SEARO 110 0.20 (.15–.27) <.0001 0.21 (.16–.28) <.0001
WPRO 147 0.35 (.27–.45) <.0001 0.41 (.32–.53) <.0001
Sample size ≥500 991 1 1
<500 97 3.68 (2.55–5.31) <.0001 2.16 (1.60–2.92) <.0001
Population ANC survey 441 1 1
ANC routine 489 0.34 (.28–.43) <.0001 0.95 (.76–1.18) .6361
Women survey 82 1.00 (.67–1.47) .9647 0.69 (.50–.97) .0312
Men survey 71 1.60 (1.05–2.42) .0250 1.21 (.86–1.70) .2843
Women and men survey 6 0.13 (.03–.55) .0057 0.19 (.06–.63) .0064
Diagnostic test RPR/TPHA 553 1 1
TPHA in ANC or FP population 21 1.96 (.94–4.10) .0730 2.41 (1.36–4.22) .0026
TPHA in non-ANC or non-FP 
population
18 15.30 (6.89–33.78) <.0001 2.71 (1.39–5.27) .0033
RPR 283 1.78 (1.39–2.27) <.0001 1.26 (1.04–1.53) .0178
Rapid treponemal-based assay 36 0.79 (.45–1.39) .4199 1.39 (.90–2.15) .1416
Assay unknown 177 0.93 (.70–1.25) .6258 0.93 (.74–1.18) .5570
Region and year AFRO and year 480 0.91 (.89–.93) <.0001 0.95 (.93–.97) <.0001
AMRO and year 205 0.90 (.86–.95) .0001 0.92 (.88–.97) .0007
EMRO and year 60 0.83 (.76–.90) <.0001 0.84 (.79–.90) <.0001
EURO and year 86 0.64 (.60–.69) <.0001 0.94 (.87–1.03) .1904
SEARO and year 110 0.91 (.86–.97) .0015 0.90 (.86–.94) <.0001
WPRO and year 147 0.98 (.94–1.04) .5687 0.97 (.93–1.01) .2298
R2 for the multivariable meta-regression model was 47.2%.
Abbreviations: AOR, adjusted odds ratio; AFRO, African Region; AMRO, Region of the Americas; ANC, antenatal care; CI, confidence interval; EMRO, Eastern Mediterranean Region; 
EURO, European Region; FP, family planning; OR, odds ratio; RPR, rapid plasma reagin; SEARO, South-East Asia Region; TPHA, Treponema pallidum hemagglutination assay; WHO, World 
Health Organization; WPRO, Western Pacific Region.
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and socioeconomic changes. Factors that may have contributed to 
a shorter active-infection duration include progressive improve-
ments in coverage of syphilis screening and treatment (notably in 
ANC), or more widespread use of antibiotics in general (including 
for non-STI infections, which sometimes cure concurrent syphi-
lis). It was noteworthy that there are considerable and persistent 
differences in prevalence by region, and that the prevalence in the 
EURO region appears to be very low (and declining), two findings 
that warrant further investigation.
While the evidence for the declines at the aggregate regional 
level is robust, this may not necessarily reflect prevalence 
declines in specific countries or specific subpopulations. 
Surveillance data indicate that syphilis prevalence is increas-
ing among MSM [4–6]. It is possible that the declines in the 
general population may reflect changes taking place in specific 
sexual networks, such as in commercial heterosexual sex net-
works, while prevalence could be increasing in other sexual 
networks, such as among MSM. There is even some evidence in 
Figure 1. Meta-analysis of male-to-female syphilis prevalence ratio. Abbreviations: AFRO, African Region; AMRO, Region of the Americas; CI, confidence interval; df, 
degrees of freedom; RE, random effects; SEARO, South-East Asia Region; WPRO, Western Pacific Region.
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/cix975/4607808
by London School of Hygiene & Tropical Medicine user
on 24 January 2018
 • CID 2017:XX (XX XXXX) • 7Trends and Predictors of Syphilis Prevalence
few countries for increased incidence among reproductive-age 
women, along with increases in congenital syphilis incidence 
[32, 33]. This highlights the need for continued vigilance in 
syphilis testing and treatment as overall population prevalence 
declines.
Our study has limitations. Although our database covered 
all regions and 154 countries, availability of data varied by re-
gion and country. While nearly all large countries contributed 
data, there were exceptions (eg, Russia in EURO). Surveys may 
have intentionally oversampled higher-STI or higher-risk areas 
and populations for reasons of public health surveillance. The 
availability of data increased with time, and the vast majority 
of data were collected after 2000. This may have biased trend 
estimates if earlier data were less representative. We could not, 
given available data, assess possible effects of age and urban–
rural differences on prevalence.
The higher prevalence in AFRO may in part be inflated by the 
higher rates of nonvenereal treponematoses infections in this 
region [34]. Serologic methods (RPR or TPHA and combin-
ation) cannot differentiate syphilis from other treponematoses 
[34]. More generally, syphilis diagnostic methods are imperfect. 
TPHA only and RPR only provide inflated prevalence estimates. 
TPHA positivity reflects ever exposure, and therefore not neces-
sarily current infection. RPR-only diagnosis can overestimate 
prevalence with false positivity with conditions such as HIV 
infection and pregnancy [35]. RPR/TPHA dual positivity, the 
gold standard, unavoidably includes a small fraction of false 
positives due to people whose syphilis infection was success-
fully treated but who remain “serofast” [36]. We attempted to 
address the diagnostic biases by including diagnostic type as 
a variable, and showing similar results in a sensitivity analysis 
that used only RPR/TPHA studies; nevertheless, the regional 
prevalence estimates and time trends are still subject to some 
bias associated with geographical and temporal variations in 
test types used across the surveys.
While we assessed the average linear trends in prevalence, the 
declines may have varied in intensity with time. We attempted 
to assess the variation in the decline rates through a sensitivity 
analysis (not shown) by incorporating a year-squared term in 
the multivariable regression, but this did not result in a superior 
model fit.
The male-to-female prevalence ratio was assessed based on 
a relatively small database (43 studies) from specific countries 
from 4 of the 6 regions—the estimated ratio may not be repre-
sentative of the global ratio. There could be also variations in 
this ratio by setting or region depending on the type of syphilis 
epidemic dynamics.
Despite these limitations, our study has key strengths. This 
syphilis database is, to our knowledge, the largest and most 
comprehensive ever assembled. Much of included data was col-
lected through standardized protocols over years, enhancing 
our ability to assess trends. Our sensitivity analyses confirmed 
the consistency and robustness of predictors and trends across 
all regions and regardless of survey characteristics.
Our findings inform global and country-level STI surveil-
lance, burden estimation, and program target setting. The 
results provided key parameter inputs for modeling, such 
as for the Spectrum-STI surveillance tool [7]. First, our 
results affirmed, based on empirical data, a 1:1 male-to-fe-
male prevalence ratio, a key modeling assumption. Second, 
our results provided diagnostic-assay adjustment fac-
tors. We found larger biases of TPHA-only and RPR-only 
screening algorithms (Table  3) than previously assumed 
(Supplementary Table 8) [7, 37]. In contrast, the adjustment 
factor for the rapid, treponemal-based assays was not stat-
istically different from 1. This supports WHO’s recommen-
dation to use this assay in settings where RPR/TPHA testing 
is not feasible or not indicated [38]. Third, after adjustment 
for confounders, we found no difference in prevalence be-
tween ANC/FP and other women (Table 3).
The WHO’s Global Health Sector Strategy on STIs, 2016–
2021 target of 90% reduction in syphilis incidence over 
2018–2030 [2] corresponds to an average annual reduction 
of 17%. This is substantially greater than the estimated an-
nual declines in prevalence (Table  3), the Spectrum-STI 
estimates from national applications [7, 31], and the 2015 
Global Burden of Disease estimates [9]. This suggests that 
the Global STI Strategy target may be ambitious or that in-
sufficient resources have been made available to achieve the 
target. It is clear also that major public health and program-
matic challenges remain on the road to elimination of con-
genital syphilis by 2030.
CONCLUSIONS
Syphilis prevalence in the general population appears to be 
declining in all regions. However, large differences across 
regions persist, with sub-Saharan Africa continuing to be the 
most affected region. The drivers and determinants of these 
declines and heterogeneities merit further study, especially the 
role that syphilis- and other STI-specific programs played.
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